Beyond the binary: integrating “real-world evidence” with randomized trials in contemporary health care

Key findings We suggest developing an integrated framework combining randomized controlled trials (RCTs) and real-world evidence (RWE), emphasizing their complementary strengths in health-care research. Currently, this integration is often ad hoc, not systematically planned or embedded within existing methodological or regulatory frameworks. We outline specific strategies focusing on prospective planning, methodological transparency (such as preregistration of RWE observational studies), and robust governance frameworks to systematically integrate these complementary evidence types. What this adds to what is known? This paper promotes evolving beyond traditional binary perspectives on evidence types (RCT vs RWE), clarifying how innovative hybrid designs, adaptive randomized trials, and pragmatic RCTs can systematically integrate RWE to enhance generalizability without sacrificing methodological rigor. We suggest approaches for integrating RWE and randomized trials (eg, external control arms, pragmatic RCTs), addressing existing knowledge gaps and reducing redundancy or fragmented integration practices. What is the implication, what should change now? Stakeholders across the health-care research ecosystem, including regulatory bodies, industry, academia, and patient communities, should adopt harmonized methodological standards and robust governance frameworks for integrating randomized trials with RWE data. Most importantly, prospective planning of integrated randomized trial and RWE approaches—rather than retrospective data assembly—must become standard practice in health-care research. Immediate priorities include developing comprehensive frameworks and prospective protocols for systematic integration, enhancing methodological transparency, and ensuring robust data governance, alongside systematic evaluation of stakeholder engagement to ensure research relevance and applicability. In addition, there must be concerted efforts to develop better methodological approaches for synthesizing different data types across diverse study designs, enabling more reliable integration of evidence from heterogeneous sources.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Epidemiology
Published
2025-05-08
DOI
https://doi.org/10.1016/j.jclinepi.2025.111821
Citations
2
Primary Topic
Primary Care and Health Outcomes
Type
article
Field-Weighted Citation Impact
5.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Beyond the binary: integrating “real-world evidence” with randomized trials in contemporary health care

Birol Emir, Declan Devane, Martin O’Donnell, Stephen M. Watt
2 citations
Journal of Clinical Epidemiology
Primary Care and Health Outcomes
5.63
article

Beyond the binary: integrating “real-world evidence” with randomized trials in contemporary health care

Birol Emir, Declan Devane, Martin O’Donnell, Stephen M. Watt
article en
2 citations

Abstract

Key findings We suggest developing an integrated framework combining randomized controlled trials (RCTs) and real-world evidence (RWE), emphasizing their complementary strengths in health-care research. Currently, this integration is often ad hoc, not systematically planned or embedded within existing methodological or regulatory frameworks. We outline specific strategies focusing on prospective planning, methodological transparency (such as preregistration of RWE observational studies), and robust governance frameworks to systematically integrate these complementary evidence types. What this adds to what is known? This paper promotes evolving beyond traditional binary perspectives on evidence types (RCT vs RWE), clarifying how innovative hybrid designs, adaptive randomized trials, and pragmatic RCTs can systematically integrate RWE to enhance generalizability without sacrificing methodological rigor. We suggest approaches for integrating RWE and randomized trials (eg, external control arms, pragmatic RCTs), addressing existing knowledge gaps and reducing redundancy or fragmented integration practices. What is the implication, what should change now? Stakeholders across the health-care research ecosystem, including regulatory bodies, industry, academia, and patient communities, should adopt harmonized methodological standards and robust governance frameworks for integrating randomized trials with RWE data. Most importantly, prospective planning of integrated randomized trial and RWE approaches—rather than retrospective data assembly—must become standard practice in health-care research. Immediate priorities include developing comprehensive frameworks and prospective protocols for systematic integration, enhancing methodological transparency, and ensuring robust data governance, alongside systematic evaluation of stakeholder engagement to ensure research relevance and applicability. In addition, there must be concerted efforts to develop better methodological approaches for synthesizing different data types across diverse study designs, enabling more reliable integration of evidence from heterogeneous sources.

Journal of Clinical EpidemiologyVol. 184
Pfizer (United States) (US), Ollscoil na Gaillimhe – University of Galway (IE), Trials Methodology Research Network (IE)
Health Research Board
Openalex Percentile: Top 5%
Primary Care and Health Outcomes
5.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.